8:00–11:45 a.m.

Preconference Activity—Facility Tours
Space is limited. Preregistration is required.
Optum clients and invited guests are given first option. More information.
NUATC—Northwestern University Affiliated Transplant Centers Tour Agenda
ACPE # 0860-0000-14-016-L01-P
OR
The University of Chicago Medicine  Tour Agenda
Support for these tours is provided by NUATC-Northwestern Affiliated Transplant Centers and The University of Chicago Medicine.

8:00 a.m.–5:00 p.m.

Conference and Exhibitor Registration—5th Floor Registration

12:00 p.m.

Lunch—Exhibit Hall, Chicago Ballroom, 5th Floor
Stop by for lunch and preview the exhibits before the official start of this year’s conference!

1:00 p.m.

Welcome and Opening Remarks—Grand Ballroom, 7th Floor

1:30 p.m.

Keynote Address: The Repressed Role of Adverse Childhood Experiences in Adult Medical Care and Costs, Vincent J. Felitti, MD, University of California
ACPE # 0860-0000-14-002-L01-P

The Adverse Childhood Experiences (ACE) study was funded by the Centers for Disease Control and Prevention (CDC) and is one of the largest investigations ever conducted to assess the relationship between childhood trauma and adult well-being. Traumatic childhood experiences have been linked to a variety of changes in brain structure and function. With a specific focus on childhood abuse, neglect, and family dysfunction, data collected from the ACE study suggests that certain experiences are major risk factors for the leading causes of illness and death. This session will explore the results of the ACE study and emphasize that prevention of some of our nation’s worst health and social problems might start with understanding that these issues might be consequences of adverse childhood experiences.

Learning Objectives:

1. Review study results from adverse childhood experiences that identified their profound negative effect on adult health and well-being.
2. State the impact of childhood trauma and violence on physical health comorbidities in adults.
3. Recognize the demonstrated major economic benefit of a small change that is frequently resisted due to practitioner discomfort.

2:30 p.m.

Bariatric Surgery for the Management of Type 2 Diabetes in Obese Patients, Sayeed Ikramuddin, MD, University of Minnesota
ACPE # 0860-0000-14-003-L01-P

Obesity has been declared a disease by the American Medical Association and is, in itself, a major medical risk that predisposes to other chronic conditions. Obesity paired with type 2 diabetes significantly increases the risk of cardiovascular disease, heart attack, stroke and other comorbidities associated with diabetes. Weight loss surgery is increasingly being used as a tool to manage type 2 diabetes. This session will discuss the question “can diabetes be surgically cured?” Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus will be presented.

Learning Objectives:

1. State comorbidities associated with obesity.
2. Discuss the long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus.
3. Describe how bariatric surgery is being used as a tool to manage type 2 diabetes.

3:15 p.m.

Break

3:30 p.m.

Advances in the Management of Intestinal Failure, George V. Mazariegos, MD, FACS, Children’s Hospital of Pittsburgh of UPMC
ACPE # 0860-0000-14-004-L01-P

An intestinal transplant is a last-resort treatment option for patients with intestinal failure who develop life-threatening complications from total parenteral nutrition (TPN). Recent advances in small bowel transplantation and nontransplant surgical techniques now offer hope of sustained survival in the future without parenteral nutrition. This session will discuss the long-term complications, as well as the clinical and financial challenges associated with intestinal failure.

Learning Objectives:

1. Discuss the long-term complications associated with intestinal failure.
2. Discuss major current indications for intestine transplantation.
3. Outline the advances in small bowel transplantation and nontransplant surgical techniques.

4:15–5:00 p.m.

Living Donor Liver Transplant: Update on Status and Current Outcomes, John R. Lake, MD, University of Minnesota Medical Center, Fairview
ACPE # 0860-0000-14-005-L01-P

The most effective therapy for end-stage liver disease is transplantation. Improved surgical techniques and the introduction of new immunosuppressive agents have enhanced the long-term results of liver transplantation, leading to an increased demand for liver transplantation that exceeds the number of potential donor organs. Liver transplantation from living donors (LDLT) is currently the most effective alternative to overcome the problem of organ shortage for adults. This session will discuss the current role of LDLT, and the surgical techniques and recipient outcomes.

Learning Objectives:

1. Examine the current status and outcomes for live donor liver transplantation.
2. Compare the use of left lobe versus right lobe for liver transplantation and the considerations for both the recipient and the donor.
3. Debate whether a change in allocation guidelines would lead to an increased need for more live donors.
4. Discuss the importance of obtaining appropriate informed consent for living donor transplantation.

5:00–7:00 p.m.

Welcome Reception and Exhibit Grand Opening—Chicago Ballroom, 5th Floor
Join us as we celebrate the opening of this year’s conference. The Welcome Reception is THE place to be as you relax with great food and beverages before heading out for a night on the town!

7:00–11:30 a.m.

Wellness Screenings and Flu Vaccinations
Preventive health screenings and flu vaccinations are available at no cost to all conference attendees. Screenings take approximately 15–20 minutes. More information.
Support for this activity is provided by Optum Biometric Solutions.

7:20–8:15 a.m.

7th Annual Wellness Walk
Start your morning with a trek along the shoreline of Lake Michigan. More information.
Support for this activity is provided by Novo Nordisk.

8:00 a.m.

Registration and Continental Breakfast—7th Floor

9:00 a.m.

Opening Remarks

9:30 a.m.

Updates in Liver and Kidney Allocation Algorithms, David C. Mulligan, MD, FACS, Yale School of Medicine
ACPE # 0860-0000-14-006-L01-P

Despite a steady increase in the number of kidney and liver transplants performed each year in the United States, there remains a significant shortage of kidneys and livers available for transplant. This has necessitated the development of allocation schema whereby priority for donor organs is given to the most severely ill patients. This session will discuss changes in the allocation policy that have been made specifically to improve equitable access to livers and kidneys for transplant.

Learning Objectives:

1. State the changes in the allocation policy for both liver and kidney transplantation.
2. Explain how these new allocation policies will impact severely ill patients.

10:30 a.m.

Break

10:45 a.m.

What Is the Status of Personalized Immunosuppression? Michael Abecassis, MD, MBA, Northwestern University Feinberg School of Medicine
ACPE # 0860-0000-14-010-L01-P

Long-term graft and patient survival are the key issues in transplantation. Liver transplantation is potentially a curative treatment for hepatocellular carcinoma (HCC). However, disease recurrence is the main challenge to the success of this treatment. Immunosuppressants that are universally used after transplantation to prevent graft rejection could potentially have a significant impact on HCC recurrence. This session will discuss the potential effects of different types of immunosuppressants on HCC recurrence and the role of personalized immunosuppressants used for patients transplanted with HCC.

Learning Objectives:

1. Define personalized Immunosuppression.
2. State potential effects of different types of immunosuppressants on HCC recurrence.

11:30 a.m.

A New Approach for Evaluating Renal Function and Predicting Risk, William McClellan, MD, Emory University
ACPE # 0860-0000-14-008-L01-P

Currently, kidney disease severity can be classified by estimated glomerular filtration rate (GFR) and albuminuria, but more accurate information regarding risk for progression to kidney failure is required for clinical decisions about testing, treatment, and referral. A new, international study from the Chronic Kidney Disease (CKD) Prognosis Consortium found that use of blood levels of cystatin C to estimate kidney function—alone or in combination with creatinine—strengthens the association between kidney function and risks of death and end-stage renal disease. This session will discuss better methods for identifying the subset of patients who are at the highest risk of adverse outcomes and how this could be useful for clinicians and other decision makers.

Learning Objectives:

1. Evaluate whether combining creatinine, cystatin C, and urine albunin-to-creatinine ratio (ACR) would improve identification of risks associated with CKD compared with creatinine alone.
2. Describe the patient populations that would most benefit from using cystatin C in GFR-estimating equations.
3. Review whether cystatin C has the potential to make estimates of GFR more accurate.
4. Discuss the limitations of estimated GFR creatinine alone for risk predication of CKD.

12:15 p.m.

Luncheon Presentation (nonaccredited/optional)—Grand Ballroom

1:45 p.m.

Dessert Reception—Exhibit Hall, Chicago Ballroom, 5th Floor
The exposition reopens, providing an opportunity to visit exhibitors showcasing their products and services surrounding complex and chronic medical conditions. A selection of desserts will be available inside the Exhibit Hall.

2:30 p.m.

Trends in the Treatment of Multiple Myeloma, Sagar Lonial, MD, Emory University
ACPE # 0860-0000-14-009-L01-P

Over the past two decades, new medications approved by the U.S. Food and Drug Administration (FDA) have transformed the way multiple myeloma is treated. This progress is unmatched in any other type of cancer. Researchers expect the picture for people with multiple myeloma to improve even more as new drugs and drug combinations are studied in clinical trials. This session will discuss recent advances in pharmacologic treatment and the roll of stem cell transplantation for multiple myeloma.

Learning Objectives:

1. Discuss recent advances in pharmacologic treatment for multiple myeloma.
2. Identify the roll of stem cell transplantation for multiple myeloma.

3:30 p.m.

Acute Lymphoblastic Leukemia (ALL) in Children: Recent Findings, Nobuko Hijiya, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago
ACPE # 0860-0000-14-007-L01-P

ALL is the most common cancer in children and is among the most curable of the pediatric malignancies. Many clinical, biological, genetic, and molecular features have been identified as having prognostic significance in the outcome of patients with ALL. Prognostic features play a critical role in directing therapy for ALL and as scientific and treatment advances are made, this area of investigation changes rapidly. This session will discuss the importance of prognostic factors that may influence the treatments used for patients with ALL, as well as review treatment protocols designed to reduce toxicity while preserving efficacy for ALL patients.

Learning Objectives:

1. Identify prognostic factors that influence treatment and outcomes for patients with ALL.
2. Discuss treatment protocols designed to reduce toxicity while preserving efficacy for patients with ALL.

4:15 p.m.

Managing Long-Term Complications After Hematopoietic Stem Cell Transplantation (HSCT), Matthew Carabasi, MD, Thomas Jefferson University Hospital
ACPE # 0860-0000-14-011-L01-P

HSCT is a medical procedure that is often performed on patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. The HSCT procedure involves the transplantation of multipotent hematopoietic stem cells, which are usually derived from bone marrow, peripheral blood, or umbilical cord blood using the patient’s own stem cells or those obtained from a healthy donor. HSCT is one of the revolutionary discoveries of medicine leading to the cure of many of the hematological malignancies and for several nonmalignant conditions. Despite all HSCT’s advances, it still remains a procedure with several potential complications, with infection being one of the major issues. This session will discuss managing long-term complications post HSCT procedure with a focus on complications from bacterial, parasitic, fungal and viral infectious diseases.

Learning Objectives:

1. Discuss the HSCT medical procedure.
2. Identify the long-term medical complications post HSCT procedure.
3. Review the prevention and treatment of HSCT infectious diseases from bacterial, parasitic, fungal and viral complications.

5:00–6:30 p.m.

Closing Reception—Exhibit Hall, Chicago Ballroom, 5th Floor
Let’s party with fabulous food and beverages as we wrap up the second day of the Annual National Conference.

8:30 a.m.

Continental Breakfast—7th Floor Foyer

9:00 a.m.

Welcome Remarks

9:15 a.m.

Preventing and Managing Chronic Conditions: Strategies to Engage and Empower Consumers to Actively Participate in Their Health Care! Victor J. Strecher, PhD, MPH, University of Michigan
ACPE # 0860-0000-14-012-L01-P

Effectively engaging consumers in healthy behavior change is critical to both their health and well-being. Healthy behavior modifications and the personal choices people make for themselves have a profound influence on the state of their health. The increasing prevalence of largely preventable chronic conditions and the suboptimal use of health care resources are strongly influenced by the behavioral choices made by consumers. While most people know what they need to do to improve their health, more often than not, they fall short when it comes to taking effective action. This session will discuss the powerful forces that impede the achievement of health care goals.

Learning Objectives:

1. Discuss the barriers that impede the achievement of health care goals.
2. Identify communication and engagement strategies that engage and empower consumers to change their behaviors and become active participants in their health care.
3. State the potential impact on the incidence of chronic conditions when effective consumer engagement is utilized to empower consumers to be active in their health care.

The Effects of the Affordable Care Act on Stem Cell Transplant (SCT), Alicia Silver, MPP, National Marrow Donor Registry (NMDP)/Be the Match
ACPE # 0860-0000-14-015-L01-P

Our current health care environment is complex with new laws and changes. The Patient Protection and Affordable Care Act, commonly called the Affordable Care Act (ACA), was signed into law in 2010, with most of the health care provisions going into effect during 2014. The ACA was designed to increase access, improve quality, and control health care costs. As a result of the ACA, SCT patients may be impacted more quickly and to a greater degree than average health care consumers. This presentation will discuss how the ACA will impact SCT patients and the role it plays from patients’ and providers’ perspectives.

Learning Objectives:

1. Review the ACA implementation and design that are impacting SCT.
2. Describe non-ACA changes and issues impacting SCT.
3. Evaluate how the ACA and non-ACA health care provisions are impacting SCT.

10:45 a.m.

Prize Drawings & Break—Grand Ballroom, 7th Floor

11:15 a.m.

Infertility: Elective Single-Embryo Transfer (eSET), Mark Leondires, MD, Reproductive Medicine Associates of Connecticut
ACPE # 0860-0000-14-013-L01-P

Infertility is a fairly common occurrence, wherein about 15 percent of couples are unable to conceive after six months to one year of attempting pregnancy. There are medical treatments that are specific to assist infertile couples with conception, such as in vitro fertilization (IVF). IVF involves the transfer of an embryo into a woman’s uterus with the hopes of leading to a healthy pregnancy. Despite a significant push from the American Society for Reproductive Medicine (ASRM) promoting eSET, more than 85 percent of IVF successes are as a result of the transfer of multiple embryos, with the attended risk of a multiple gestation. This session will review the infertility standard of care pathway, the benefits of eSET and strategies to increase the use of eSET.

Learning Objectives:

1. Evaluate the infertility pathway standard of care of single-embryo transfers.
2. State the benefits of single-embryo transfers.
3. Apply strategies to increase the use of single-embryo transfers.

12:00 p.m.

Ventricular Assist Devices (VADs): Utilization, Management, and Clinical and Financial Outcomes, Scott C. Silvestry, MD, Barnes-Jewish Hospital
ACPE # 0860-0000-14-014-L01-P

Although heart transplants are considered the gold standard of treatment for advanced heart failure, the incidence of transplant is limited due to stringent selection criteria and the scarcity of acceptable donors. Because of this, VADs are showing trends of increasing utilization, expanding the previously limited scope of treatment options for patients with advanced heart failure.

While successful VAD implantation has many potential benefits it also carries risks and posttransplant case management is key for effective utilization. This session will discuss the complexity of patient management, patient selection, prior authorization, costs implications and outcomes.

Learning Objectives:

1. Discuss the benefits and risks of VAD implantation.
2. Outline effect case management strategies post VAD implantation.
3. Compare cost implications of poor versus effective management post VAD implantation and their outcomes.

1:00 p.m.

Adjourn